Biomarin Pharmaceutical (BMRN) Stake Has Boosted by Argentiere Capital Ag; Zions Bancorporation (ZIONZ) Holder Maltese Capital Management Lowered Its Position by $2.44 Million

June 20, 2018 - By Jacob Smith

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo

Argentiere Capital Ag increased its stake in Biomarin Pharmaceutical Inc (BMRN) by 40% based on its latest 2018Q1 regulatory filing with the SEC. Argentiere Capital Ag bought 20,000 shares as the company’s stock rose 10.05% while stock markets declined. The hedge fund held 70,000 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $5.68 million, up from 50,000 at the end of the previous reported quarter. Argentiere Capital Ag who had been investing in Biomarin Pharmaceutical Inc for a number of months, seems to be bullish on the $16.90 billion market cap company. The stock increased 0.04% or $0.04 during the last trading session, reaching $95.62. About 1.42 million shares traded or 4.22% up from the average. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.91% since June 20, 2017 and is uptrending. It has underperformed by 6.66% the S&P500. Some Historical BMRN News: 24/05/2018 – BIOMARIN PHARMACEUTICAL INC – PALYNZIQ IS EXPECTED TO BE AVAILABLE IN UNITED STATES BY END OF JUNE; 22/05/2018 – Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study against SOC $BMRN; 02/05/2018 – BioMarin Presenting at Bank of America Conference May 15; 25/04/2018 – BioMarin Pharmaceutical 1Q Loss/Shr 26c; 25/04/2018 – BIOMARIN 1Q LOSS/SHR 26C; 28/03/2018 – European Medicines Agency (EMA) Accepts BioMarin’s Marketing Application for Pegvaliase MAA for Treatment of Phenylketonuria (P; 10/05/2018 – Cramer also sits down with the CEOs of Groupon and BioMarin; 21/03/2018 – BioMarin Closes Above 50-Day Moving Average: Technicals; 24/05/2018 – BIOMARIN RECEIVES STANDARD APPROVAL FOR PALYNZIQ; 24/05/2018 – BioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease

Maltese Capital Management Llc decreased its stake in Zions Bancorporation (ZIONZ) by 18.28% based on its latest 2018Q1 regulatory filing with the SEC. Maltese Capital Management Llc sold 152,200 shares as the company’s stock 0.00% . The institutional investor held 680,200 shares of the major banks company at the end of 2018Q1, valued at $11.22 million, down from 832,400 at the end of the previous reported quarter. Maltese Capital Management Llc who had been investing in Zions Bancorporation for a number of months, seems to be less bullish one the $3.96B market cap company. The stock decreased 5.55% or $1.15 during the last trading session, reaching $19.61. About 400 shares traded or Infinity% up from the average. Zions Bancorporation WT EXP 111418 (NASDAQ:ZIONZ) has 0.00% since June 20, 2017 and is . It has underperformed by 12.57% the S&P500.

Maltese Capital Management Llc, which manages about $1.71B and $1.47 billion US Long portfolio, upped its stake in Summit Financial Group Inc (NASDAQ:SMMF) by 27,900 shares to 55,000 shares, valued at $1.38 million in 2018Q1, according to the filing. It also increased its holding in Farmers Natl Banc Corp (NASDAQ:FMNB) by 180,269 shares in the quarter, for a total of 243,069 shares, and has risen its stake in Bancfirst Corp (NASDAQ:BANF).

More important recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” on May 25, 2018, also Nasdaq.com published article titled: “3 Biotech Stocks Up in the Past Month on Industry Turnaround”, Seekingalpha.com published: “BioMarin Keeps The FDA Approval Train Rolling” on May 29, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was released by: Bizjournals.com and their article: “Why this biotech exec broke down on a conference call over company’s new rare-disease drug” with publication date: May 31, 2018.

Argentiere Capital Ag, which manages about $464.87 million and $234.45M US Long portfolio, decreased its stake in Western Digital Corp (NASDAQ:WDC) by 5,000 shares to 10,000 shares, valued at $923,000 in 2018Q1, according to the filing. It also reduced its holding in Nxp Semiconductors N V (NASDAQ:NXPI) by 200,000 shares in the quarter, leaving it with 140,000 shares, and cut its stake in Monsanto Co New (NYSE:MON).

Among 28 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. BioMarin Pharmaceutical had 99 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Friday, February 23 by Morgan Stanley. On Thursday, November 3 the stock rating was initiated by Deutsche Bank with “Buy”. SunTrust maintained it with “Buy” rating and $115.0 target in Thursday, October 19 report. The rating was maintained by Credit Suisse on Thursday, October 19 with “Buy”. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Wednesday, August 30 by Citigroup. Stifel Nicolaus maintained the shares of BMRN in report on Thursday, August 3 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Thursday, August 24 report. Cowen & Co maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, August 25 with “Buy” rating. Deutsche Bank maintained it with “Buy” rating and $124 target in Friday, February 23 report. The company was maintained on Tuesday, July 11 by Cowen & Co.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>